StockData
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. (NRSN) shareholders

NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 4/30
$1.37−0.14 (-9.27%)

Close on Nov 18, 2026Market cap $2.52MP/E –Yield –

Ownership

Who owns NeuroSense Therapeutics's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
2 buys · 0 sales
Net bought $400.00K

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Alon Ben-Noon3,072,60019.98%13G (passive) amendmentDec 31, 2023
Rimon Gold Assets Ltd.
Joint filing with Abir Raveh (9.99%), Goldfinger Trust (9.99%)
2,303,7299.99%13G (passive)Dec 9, 2024
Ariel Gordon1,060,5616.90%13G (passive) amendmentDec 31, 2023

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares ownedLatest filing
Alon Ben-NoonChief Executive Officer4,534,233Jun 17, 2026
Or EisenbergChief Financial Officer1,504,050Jun 17, 2026
Niva Russek-BlumChief Technology Officer39,881Mar 30, 2026
Hagit BinderGeneral Manager521,806Mar 30, 2026
Ferenc TracikChief Medical Officer189,618Mar 18, 2026
Revital Mandil-LevinDirector52,526Mar 31, 2026
Mark LeuchtenbergerDirector128,000Mar 18, 2026
Cary J. ClaiborneDirector60,000Mar 18, 2026
Roy GolanDirector60,000Mar 18, 2026
Christine A. PellizzariDirector99,898Mar 18, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Alon Ben-Noon
Chief Executive Officer
Jun 16, 2026Buy+250,000$0.80$200.00K4,534,233
Or Eisenberg
Chief Financial Officer
Jun 16, 2026Buy+250,000$0.80$200.00K1,504,050
Or Eisenberg
Chief Financial Officer
Mar 26, 2026Award+200,000––1,254,050
Niva Russek-Blum
Chief Technology Officer
Mar 26, 2026Award+200,000––467,953
Hagit Binder
General Manager
Mar 26, 2026Award+200,000––521,806

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.1
At 0M shares a day
Change since last report
+4.1%
From 0M shares
Short volume, 20 days
34.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of NeuroSense Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 181,403 shares on Sep 8, 2026 over the last 90 days.

See a number that looks wrong?